Tramadol is an FDA approved medication for pain relief. It has specific indications for moderate to severe pain. It is considered a class IV drug by the FDA and has been since July 7th, 2014. Due to possible abuse and addiction potential, limitations to its use should be for pain that is refractive to other pain medication, such as non-opioid pain medication. There are two forms of tramadol: extended-release and immediate release. The immediate release is not for use as an "as needed" medication; instead, it is for pain of less than a week duration. For pain lasting more than a week, extended-release is the therapeutic choice — the indication for extended-release is for pain control under 24-hour management or an extended period.
Off-label, the drug is useful for premature ejaculation and restless leg syndrome refractory to other medication. For the off-label use of tramadol for premature ejaculation, both sporadic and daily use is effective for the treatment of the condition. Patients indicate a preference for "as needed"therapy for premature ejaculation due to the lack of side effects compared to daily use of tramadol.
Tramadol is an opioid and like other opioids selectively bind to different opiate receptors in the central nervous system. The liver enzyme, CYP2D6, converts tramadol to its active metabolite M1, which has a stronger affinity for the mu receptor compared to the inactive form. Tramadol does not bind to the mu receptor as much as morphine. Unlike other opioids, tramadol does not reverse its course completely after the administration of naloxone. Along with the partial agonist activity on the opioid receptors, it also inhibits the reuptake of serotonin and norepinephrine.
There are two different formulations of tramadol: extended-release and immediate release. The extended-release and immediate release both come in a capsule form. For the extended-release, patients should receive counseling on the drug; it should not be chewed, crushed, dissolved or spit before administration. Administration of both formulations can be without regard to food, but the administration of the extended-release formula should be at a consistent time each day.
Half-life: Six Hours
Time for the drug to reach peak concentration: Extended Release: 12 hours
Immediate Release: 1.6-1.9 hours
Dosages: Extended Release: 100mg, 200mg, 300mg
Immediate Release: 50mg
The organs most commonly affected by the use of tramadol are the central nervous system, neuromuscular, and gastrointestinal. The cardiovascular system, dermatologic system, endocrine, genitourinary, and the visual system are also affected by the use of tramadol.
The most prevalent side effects are nausea, dizziness, constipation, vomiting, somnolence, and headache. They tend to occur during the initial treatment rather than maintenance doses of the drug.
Serious side effects include respiratory depression which may result in death.
Tramadol is contraindicated in patients who have had a hypersensitivity reaction to any opioid. Patients under the age of twelve should not use the medication and patients under the age of eighteen should not be given the medication if they have had a history of tonsillectomy or adenoidectomy. Because tramadol can cause respiratory depression, patients who have a history of severe respiratory depression, or bronchial asthma with the absence of necessary equipment, should avoid taking tramadol. Patients currently on MOAs or people who have been on MOAs in the past fourteen days should not receive tramadol. Patients on tricyclic antidepressants should also not take tramadol. People who have Gl obstruction should not use tramadol.
Due to the potential side effect of respiratory depression patients should not use alcohol, benzodiazepines, or other CNS depressants at the same time. Concurrent use of these drugs can exacerbate respiratory depression and can lead to coma and death. Because tramadol is hepatically metabolized, concurrent use of other drugs that undergo hepatic metabolism should be avoided. Genetic variations of CYP2D6 can affect the severity of the drug. Using other drugs that are metabolized by these enzymes can also potentiate the side effects.
Prior to the administration of tramadol, it is essential to get the patient's baseline liver function tests (AST and ALT), because hepatic metabolism of the drug can lead to hepatotoxicity. Recommendations also include psychiatric evaluation for suicidal ideations, abuse, or misuse of tramadol before prescribing the medication.
After administration, the practitioner should continue to monitor the patient’s liver function, blood pressure, respiratory system, and mental status. Due to the addictive potential of the drug, continued monitoring of the risks and benefits of tramadol use should take place every three months.
Primarily, the initial treatment is to maintain a patent airway and to maintain adequate ventilation through assisted or controlled ventilation. Like other opioids, naloxone can provide partial reversal of the side effects of tramadol.
Naloxone is a competitive antagonist of the mu, kappa, and sigma receptor that tramadol and other opioids bind to, with the highest affinity for the mu receptor. It is available in oral or IV formulations. The oral form has low bioavailability compared to the other formulations. The half-life of naloxone is shorter than tramadol so repeat doses may be necessary. Although this drug may be used to decrease respiratory and central nervous system depression, it may increase the risk for seizures.
Managing opioid overdose such as tramadol requires a team effort including numerous specialties. Without proper management, an overdose of tramadol or other opioids often leads to death. The process of treating tramadol overdose or misuse starts prior to initial administration. The incorrect use of prescriptions is a significant contributor to opioid use disorder so the proper administration of the drug can help prevent drug use disorder. Management of pain is vital in the treatment of patients and tramadol can provide valuable relief for this population. Although tramadol has a comparatively low risk of misuse, there are still cases of patients with no history of opioid use disorder developing the condition while taking the medication.(Level V) Therefore, reliance upon the whole healthcare team, instead of just the physician, is in order to prevent the mismanagement of prescriptions. The use of government policy changes that initiated prescription drug monitoring programs has resulted in a decrease in drug misuse as well as drug fatalities. (Level II)
Case managers, physicians, pharmacists, and other members of the healthcare team are essential in preventing the abuse of prescriptions. Case managers and nurses are vital in helping prevent physicians from over-prescribing tramadol and other opioids. These functions are crucial in seeing the potential for use disorder in patients. They can help prevent opioid misuse by doing the following:
Pharmacists are also critical in the management of tramadol abuse. They can help prevent the misuse of prescriptions by:
|||Martyn-St James M,Cooper K,Kaltenthaler E,Dickinson K,Cantrell A,Wylie K,Frodsham L,Hood C, Tramadol for premature ejaculation: a systematic review and meta-analysis. BMC urology. 2015 Jan 30 [PubMed PMID: 25636495]|
|||Lauerma H,Markkula J, Treatment of restless legs syndrome with tramadol: an open study. The Journal of clinical psychiatry. 1999 Apr [PubMed PMID: 10221285]|
|||Khan AH,Rasaily D, Tramadol use in premature ejaculation: daily versus sporadic treatment. Indian journal of psychological medicine. 2013 Jul [PubMed PMID: 24249927]|
|||Dayer P,Desmeules J,Collart L, [Pharmacology of tramadol]. Drugs. 1997 [PubMed PMID: 9190321]|
|||Langley PC,Patkar AD,Boswell KA,Benson CJ,Schein JR, Adverse event profile of tramadol in recent clinical studies of chronic osteoarthritis pain. Current medical research and opinion. 2010 Jan [PubMed PMID: 19929615]|
|||Arafa MH,Atteia HH, Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6) are associated with long term tramadol treatment-induced oxidative damage and hepatotoxicity. Toxicology and applied pharmacology. 2018 May 1 [PubMed PMID: 29555325]|
|||Lagard C,Malissin I,Indja W,Risède P,Chevillard L,Mégarbane B, Is naloxone the best antidote to reverse tramadol-induced neuro-respiratory toxicity in overdose? An experimental investigation in the rat. Clinical toxicology (Philadelphia, Pa.). 2018 Aug [PubMed PMID: 29148295]|
|||Ojha R,Bhatia SC, Tramadol dependence in a patient with no previous substance history. Primary care companion to the Journal of clinical psychiatry. 2010 [PubMed PMID: 20582298]|
|||Johnson H,Paulozzi L,Porucznik C,Mack K,Herter B, Decline in drug overdose deaths after state policy changes - Florida, 2010-2012. MMWR. Morbidity and mortality weekly report. 2014 Jul 4 [PubMed PMID: 24990490]|
|||Sortedahl C,Krsnak J,Crook MM,Scotton L, Case Managers on the Front Lines of Opioid Epidemic Response: Advocacy, Education, and Empowerment for Users of Medical and Nonmedical Opioids. Professional case management. 2018 Sep/Oct [PubMed PMID: 30059464]|